Dacomitinib

{
  "id": "MLC-T-ONC-002268",
  "term": "Dacomitinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat non-small cell lung cancer that has spread, has not already been treated, and has certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. Dacomitinib blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called PF-00299804 and Vizimpro.",
    "A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors."
  ],
  "synonyms": [
    "PF-00299804",
    "Vizimpro",
    "EGFR inhibitor PF-00299804"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dacomitinib/"
}